{"id":"bleomycin-and-vincristine-bv","safety":{"commonSideEffects":[{"rate":"40-80","effect":"Myelosuppression (neutropenia, thrombocytopenia)"},{"rate":"10-40","effect":"Pulmonary toxicity / pneumonitis"},{"rate":"60-90","effect":"Nausea and vomiting"},{"rate":"20-50","effect":"Peripheral neuropathy"},{"rate":"30-60","effect":"Alopecia"},{"rate":"20-40","effect":"Mucositis"},{"rate":"10-30","effect":"Fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Bleomycin is a glycopeptide antibiotic that intercalates into DNA and causes strand breaks, leading to cell death. Vincristine is a vinca alkaloid that binds to tubulin and prevents microtubule assembly, arresting cells in metaphase. Together, they provide synergistic cytotoxic effects against malignant cells.","oneSentence":"Bleomycin and Vincristine is a combination chemotherapy regimen that damages DNA and disrupts microtubule formation to kill rapidly dividing cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:04:32.062Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Lymphomas (Hodgkin and non-Hodgkin)"},{"name":"Testicular cancer"},{"name":"Cervical cancer"},{"name":"Other solid tumors and hematologic malignancies"}]},"trialDetails":[{"nctId":"NCT02166463","phase":"PHASE3","title":"Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-03-19","conditions":"Ann Arbor Stage IIB Hodgkin Lymphoma, Ann Arbor Stage IIIB Hodgkin Lymphoma, Ann Arbor Stage IVA Hodgkin Lymphoma","enrollment":600},{"nctId":"NCT01435018","phase":"PHASE3","title":"Three Chemo Regimens as an Adjunct to ART for Treatment of Advanced AIDS-KS","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2013-10-01","conditions":"HIV-1 Infection","enrollment":334}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":35,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Bleomycin and Vincristine (BV)","genericName":"Bleomycin and Vincristine (BV)","companyName":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","companyId":"advancing-clinical-therapeutics-globally-for-hiv-aids-and-other-infections","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bleomycin and Vincristine is a combination chemotherapy regimen that damages DNA and disrupts microtubule formation to kill rapidly dividing cancer cells. Used for Lymphomas (Hodgkin and non-Hodgkin), Testicular cancer, Cervical cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}